Press Release: U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne
U.S. Commercial Launch of Cash-Pay Product Anticipated in Mid-2019 Duluth, GA – September 17, 2018 – Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance…
